

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Young et al.	Confirmation No.:	4680
Serial No.:	10/585,772	Art Unit:	1635
Filed:	July 12, 2006	Examiner:	Shin, Dana H
Customer No.:	21559		
Title:	ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCATASE R2 AND USES THEREOF IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. Please charge Deposit Account No. 03-2095 in the amount of \$ 180.00 for payment of the fee set forth in 37 C.F.R. § 1.17(p).

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: October 13, 2009



Kristina Boker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045